AstraZeneca (BUE:AZN) Cyclically Adjusted Revenue per Share: ARS12,381.63 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:AZN AstraZeneca PLC BUE:AZN
76 GF Score
Price ARS61,550.00
GF Value ARS71,144.56
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted Revenue per Share?

AstraZeneca BUE:AZN -1.01% 76 Cyclically Adjusted Revenue per Share is ARS12,381.63 as of Jun. 2026. GuruFocus rates BUE:AZN with a GF Score™ of 76/100 and a GF Value™ of ARS71,144.56 (Modestly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AstraZeneca's adjusted revenue per share for the three months ended in Jun. 2026 was ARS14,606.941. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS12,381.63 for the trailing ten years ended in Jun. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted Revenue Growth Rate was 8.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AstraZeneca was 9.90% per year. The lowest was -0.20% per year. And the median was 5.30% per year.

As of today (2026-08-18), AstraZeneca's current stock price is ARS61550.00. AstraZeneca's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ARS12,381.63. AstraZeneca's Cyclically Adjusted PS Ratio of today is 4.97.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


AstraZeneca  (BUE:AZN) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=61550.00/12381.63
=4.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AstraZeneca was 6.86. The lowest was 2.82. And the median was 5.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AstraZeneca Cyclically Adjusted Revenue per Share Related Terms


AstraZeneca Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted Revenue per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 38.93 34.04 38.83 7,761.72 11,587.80

AstraZeneca Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,149.15 11,758.80 11,587.80 11,408.34 12,381.63

BUE:AZN vs LLY, JNJ, ABBV: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted PS Ratio falls into.


BUE:AZN
76GF Score
AstraZeneca PLC BUE:AZN
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=14606.941/142.3000*142.3000
=14,606.941

Current CPI (Jun. 2026) = 142.3000.

AstraZeneca Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 67.149 101.500 94.141
201612 69.934 102.200 97.374
201703 65.821 102.700 91.201
201706 65.783 103.500 90.444
201709 86.193 104.300 117.596
201712 86.860 105.000 117.716
201803 82.345 105.100 111.491
201806 101.473 105.900 136.351
201809 155.096 106.600 207.037
201812 190.965 107.100 253.728
201903 169.277 107.000 225.123
201906 198.297 107.900 261.517
201909 273.066 108.400 358.462
201912 303.375 108.500 397.883
202003 300.372 108.600 393.581
202006 327.179 108.800 427.919
202009 372.219 109.200 485.044
202012 459.273 109.400 597.391
202103 499.913 109.700 648.474
202106 590.805 111.400 754.682
202109 644.851 112.400 816.391
202112 776.563 114.700 963.426
202203 783.451 116.500 956.953
202206 830.817 120.500 981.122
202209 978.800 122.300 1,138.865
202212 1,204.393 125.300 1,367.798
202303 1,377.658 126.800 1,546.063
202306 1,756.308 129.400 1,931.396
202309 2,577.965 130.100 2,819.711
202312 2,780.694 130.500 3,032.128
202403 6,847.473 131.600 7,404.220
202406 7,426.910 133.000 7,946.235
202409 8,254.502 133.500 8,798.619
202412 9,628.624 135.100 10,141.771
202503 9,279.507 136.100 9,702.233
202506 11,009.513 138.400 11,319.752
202509 13,215.609 138.900 13,539.101
202512 14,396.951 139.900 14,643.932
202603 13,694.024 140.800 13,839.912
202606 14,606.941 142.300 14,606.941

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS12,381.63 mean?
AstraZeneca (BUE:AZN) has a Cyclically Adjusted Revenue per Share of ARS12,381.63 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted Revenue per Share too high?
AstraZeneca's current Cyclically Adjusted Revenue per Share is ARS12,381.63. Overall, AstraZeneca has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted Revenue per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted Revenue per Share of ARS12,381.63 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted Revenue per Share is ARS12,381.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (BUE:AZN) is currently considered Modestly Undervalued. The stock's GF Value™ is ARS71,144.56, compared to a current price of ARS61,550.00 — trading 13.5% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS12,381.63. AstraZeneca's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For AstraZeneca (BUE:AZN), the current Cyclically Adjusted Revenue per Share is ARS12,381.63 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (BUE:AZN) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of ARS61,550.00 is trading 13.5% below its estimated GF Value™ of ARS71,144.56. GuruFocus considers AstraZeneca to be Modestly Undervalued.

Key valuation signals for BUE:AZN:

  • Cyclically Adjusted Revenue per Share: ARS12,381.63
  • GF Value™: ARS71,144.56 vs. price of ARS61,550.00 (13.5% below fair value)
  • GF Score™: 76/100 with 1 warning sign

No single metric tells the full story. See the BUE:AZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
76GF Score

Get the complete analysis for BUE:AZN

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS61,550.00
Price
ARS71,144.56
GF Value